Verve FDA request ‘provides fodder for both bulls and bears,’ says Stifel

Stifel analyst Dae Gon Ha contends that Verve Therapeutics’ 8K filing detailing FDA’s requests in conjunction with the VERVE-101 clinical hold "provides fodder for both bulls and bears" and added that his follow-up with management leaves "some uncertainty" that "could fuel the bears." However, the fact that the FDA’s list of requests is "finite and addressable" keeps him "optimistically inclined" towards getting the FDA on-board, said Gon Ha, who has a Buy rating and $24 price target on Verve shares, which are down $5.30, or 22%, to $18.70 in morning trading.